Сompany news
We consider that NIVIRON is ready to raise funding. We formed the necessary team (!!For the implementation of the next stage), received the rights to new technologies, prepared the budget and its justification, found the necessary contractors. We have outlined everything in our investment deck, which you can get here
This type of organization will allow us to attract funding at an earlier stage and, as a result, will allow us to create our own technologies. Our first goal is to create a technology for the delivery of oncolytic viruses.
We agreed with the Assistant Professor of the University of Arkansas for Medical Sciences — Bolni Marius Nagalo, Ph.D. about cooperation. Dr. Nagalo will lead the development and preclinical trials of our technologies. You can learn more about Dr. Nagalo on our team page.
We are pleased to introduce Darrick Carter, Ph.D., University of Washington in the School of Medicine and in Global health. Dr. Carter has extensive experience in the biotech business (he is the founder of five biotech companies including: HDT Bio Corp., Compliment Corp., Dharma Therapeutics, and PAI Life Sciences Inc., one of which went public). He also has extensive experience in clinical and preclinical trials. Darrick Carter will be our consultant. You can learn more about Dr. Carter on our team page.
We have signed an agreement to license technology based on oncolytic Coxsackievirus, which has shown good efficacy and safety in animal testing. Now our task is to bring this technology to the market, providing access to patients with cancer.
We are pleased to announce that Alexis Kafando, Ph.D., a scientist at the University of Montreal, will join Niviron Inc. as principal investigator for our scientific research. You can learn more about Dr. Kafando on our team page.
Focus — cancer. We have chosen the business model and focus of our company. We decided to focus our attention on cancer therapy with oncolytic viruses. In our understanding, this is one of the most promising types of cancer therapies that can completely cure cancer therapy with oncolytic viruses.
We raised the first investments in order to ensure the company’s viability for the time when we are assembling the first team and looking for technology for licensing.
MAJOR CANDIDATE Legal data Possible Advantages Doesn’t cause severe side effects. Could potentially be targeted to several types of cancer. It can potentially become a platform for the creation of new (more effective) virus strains. Disadvantages Patent of 2017. Possibly should be used with other recognized treatments. Partial lysis of cancer cells, i.e., does not lead to complete healing. It is only prolong the patient’s life. What is — The Coxsackie Group B3 Virus Strain CVB3 PD-0 The Fundamental Indication — Colorectal cancer Additional indications — Pancreatic cancer, Lung cancer Inventors — Henry Fechner, DVM Ahmet Hazini Vanessa Brueckner Patent
MAJOR CANDIDATE Legal data Possible Advantages Doesn’t cause severe side effects. Could potentially be targeted to several types of cancer. It can potentially become a platform for the creation of new (more effective) virus strains. Disadvantages Patent of 2017. Possibly should be used with other recognized treatments. Partial lysis of cancer cells, i.e., does not lead to complete healing. It is only prolong the patient’s life. What is — The Coxsackie Group B3 Virus Strain CVB3 PD-0 The Fundamental Indication — Colorectal cancer Additional indications — Pancreatic cancer, Lung cancer Inventors — Henry Fechner, DVM Ahmet Hazini Vanessa Brueckner Patent
MAJOR CANDIDATE Legal data Possible Advantages Doesn’t cause severe side effects. Could potentially be targeted to several types of cancer. It can potentially become a platform for the creation of new (more effective) virus strains. Disadvantages Patent of 2017. Possibly should be used with other recognized treatments. Partial lysis of cancer cells, i.e., does not lead to complete healing. It is only prolong the patient’s life What is — The Coxsackie Group B3 Virus Strain CVB3 PD-0 The Fundamental Indication — Colorectal cancer Additional indications — Pancreatic cancer, Lung cancer Inventors — Henry Fechner, DVM Ahmet Hazini Vanessa Brueckner Patent
WHAT IS The Coxsackie Group B3 Virus Strain CVB3 PD-0 Possible Advantages Doesn’t cause severe side effects. Could potentially be targeted to several types of cancer. It can potentially become a platform for the creation of new (more effective) virus strains. Disadvantages Patent of 2017. Possibly should be used with other recognized treatments. Partial lysis of cancer cells, i.e., does not lead to complete healing. It is only prolong the patient’s life. The Fundamental Indication Colorectal cancer Additional indications Pancreatic cancer Lung cancer Inventors Henry Fechner, DVM Ahmet Hazini Vanessa Brueckner Patent owner Technical University of Berlin Patent number US
We consider that NIVIRON is ready to raise funding. We formed the necessary team (!!For the implementation of the next stage), received the rights to new technologies, prepared the budget and its justification, found the necessary contractors. We have outlined everything in our investment deck, which you can get here
This type of organization will allow us to attract funding at an earlier stage and, as a result, will allow us to create our own technologies. Our first goal is to create a technology for the delivery of oncolytic viruses.
We agreed with the Assistant Professor of the University of Arkansas for Medical Sciences — Bolni Marius Nagalo, Ph.D. about cooperation. Dr. Nagalo will lead the development and preclinical trials of our technologies. You can learn more about Dr. Nagalo on our team page.
We are pleased to introduce Darrick Carter, Ph.D., University of Washington in the School of Medicine and in Global health. Dr. Carter has extensive experience in the biotech business (he is the founder of five biotech companies including: HDT Bio Corp., Compliment Corp., Dharma Therapeutics, and PAI Life Sciences Inc., one of which went public). He also has extensive experience in clinical and preclinical trials. Darrick Carter will be our consultant. You can learn more about Dr. Carter on our team page.
We have signed an agreement to license technology based on oncolytic Coxsackievirus, which has shown good efficacy and safety in animal testing. Now our task is to bring this technology to the market, providing access to patients with cancer.
We are pleased to announce that Alexis Kafando, Ph.D., a scientist at the University of Montreal, will join Niviron Inc. as principal investigator for our scientific research. You can learn more about Dr. Kafando on our team page.
Focus — cancer. We have chosen the business model and focus of our company. We decided to focus our attention on cancer therapy with oncolytic viruses. In our understanding, this is one of the most promising types of cancer therapies that can completely cure cancer therapy with oncolytic viruses.
We raised the first investments in order to ensure the company’s viability for the time when we are assembling the first team and looking for technology for licensing.
